Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar

Inflamm Bowel Dis. 2020 Jul 17;26(8):e83-e84. doi: 10.1093/ibd/izaa128.
No abstract available

Keywords: BS2; CT-P13; Crohn’s disease; infliximab biosimilar; psoriasis.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Biosimilar Pharmaceuticals / administration & dosage
  • Biosimilar Pharmaceuticals / adverse effects*
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Disease Progression
  • Drug Substitution / adverse effects*
  • Humans
  • Infliximab / administration & dosage
  • Infliximab / adverse effects*
  • Male
  • Medical Illustration
  • Psoriasis / chemically induced*
  • Psoriasis / complications

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • SB2 infliximab
  • Infliximab